Charles Schwab Investment Management Inc. Buys 32,347 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Charles Schwab Investment Management Inc. grew its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,155,080 shares of the biopharmaceutical company's stock after purchasing an additional 32,347 shares during the period. Charles Schwab Investment Management Inc. owned about 0.88% of Dynavax Technologies worth $14,750,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Smartleaf Asset Management LLC grew its position in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 2,034 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after buying an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in shares of Dynavax Technologies during the fourth quarter valued at $71,000. Nisa Investment Advisors LLC raised its position in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after buying an additional 1,076 shares during the period. Finally, KBC Group NV raised its position in Dynavax Technologies by 68.7% during the fourth quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company's stock valued at $90,000 after buying an additional 2,857 shares during the period. Institutional investors and hedge funds own 96.96% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DVAX shares. HC Wainwright reaffirmed a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair reiterated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and dropped their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Stock Up 0.1 %

DVAX traded up $0.02 during midday trading on Monday, hitting $13.84. 1,401,971 shares of the company's stock traded hands, compared to its average volume of 1,994,885. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a market cap of $1.72 billion, a PE ratio of 76.89 and a beta of 1.23. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.63. The stock's fifty day simple moving average is $13.22 and its 200-day simple moving average is $12.41.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts' consensus estimates of $0.05. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. As a group, equities analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.